Peripheral Vascular Devices Market Report

To learn more about this report, Download Free Sample Report

Global Peripheral Vascular Devices Market Size

The global peripheral vascular devices market size was valued at USD 10,232.24 million in 2025. The size of the peripheral vascular devices market is forecasted to be worth USD 19,130.39 million by 2034 and USD 10.968.96 million in 2026, growing at a CAGR of 7.2% between 2026 to 2034. 

According to the Centers for Disease Control and Prevention, peripheral artery disease affects approximately 8.5 million Americans aged 40 and older, creating a substantial clinical burden that necessitates minimally invasive interventions. The peripheral vascular devices market encompasses a specialized array of medical instruments, including stents, balloons, catheters, and atherectomy systems, designed to diagnose and treat diseases affecting blood vessels outside the heart and brain. This market is distinct due to its reliance on advanced endovascular technologies that offer alternatives to open surgical bypass procedures. According to the National Heart, Lung, and Blood Institute, more than 300,000 surgical or endovascular lower extremity revascularization procedures are performed annually among Medicare beneficiaries with lower extremity peripheral artery disease without limb-threatening ischemia, reflecting the continued use of minimally invasive vascular treatments. These procedural volumes directly drive the demand for high-precision delivery systems and durable implants. The industry is increasingly shifting toward drug-coated technologies, which reduce restenosis rates and improve long-term patency. According to a study published in the Journal of Vascular Surgery, patients receiving drug-eluting stents for femoropopliteal disease had a 50% lower risk of target lesion revascularization than patients receiving bare-metal stents in a propensity-matched analysis. This technological evolution ensures that the peripheral vascular devices market remains dynamic and responsive to the rising prevalence of diabetes and aging populations while maintaining a focus on improving limb salvage rates and patient quality of life.

MARKET DRIVERS

Rising Prevalence of Diabetes and Chronic Kidney Disease

The escalating global incidence of diabetes mellitus and chronic kidney disease majorly drives the peripheral vascular devices market expansion by accelerating the onset of peripheral artery disease and critical limb ischemia. According to the International Diabetes Federation, approximately 537 million adults were living with diabetes in 2021, a number projected to rise to 643 million by 2030, creating a vast population at risk for vascular complications. Diabetic patients are two to four times more likely to develop peripheral artery disease due to accelerated atherosclerosis and calcification of the lower extremity arteries. This statistical correlation directly translates into increased demand for angioplasty balloons and stents required to restore blood flow and prevent amputation. Furthermore, chronic kidney disease exacerbates vascular calcification, making standard interventions more complex and requiring specialized devices such as lithotripsy systems. According to the National Kidney Foundation, 37 million adults in the United States have chronic kidney disease, and approximately 90% of people with the condition are unaware of it. These comorbidities create a recurring need for device-assisted therapies rather than one-time fixes. Consequently, the peripheral vascular devices market benefits from a structural driver where metabolic disorders sustain high procedural volumes and drive innovation in devices capable of treating heavily calcified lesions.

Aging Population and Increased Life Expectancy

The demographic shift toward an older population further supports the peripheral vascular devices market expansion by expanding the cohort susceptible to age-related vascular degeneration and arterial stiffness. According to the United Nations Department of Economic and Social Affairs, the global population aged 65 and over is projected to increase from 761 million in 2021 to 1.6 billion by 2050, leading to a higher prevalence of atherosclerotic conditions. Aging is a primary risk factor for peripheral artery disease as arterial walls lose elasticity and plaque accumulation increases over time. The statistical growth in the elderly population ensures a steady pipeline of patients requiring diagnostic angiography and therapeutic interventions. Additionally, increased life expectancy means that patients are more likely to seek treatment for mobility-limiting claudication to maintain an active lifestyle rather than accepting disability. According to the American Heart Association, almost 20% of adults over the age of 70 years have peripheral artery disease. This demographic reality drives demand for both emergency limb-saving procedures and elective interventions for quality-of-life improvement. Thus, the peripheral vascular devices market is propelled by demographic inevitabilities where longevity creates sustained demand for vascular care solutions.

MARKET RESTRAINTS

High Cost of Advanced Drug-Coated Technologies

The substantial premium associated with drug-coated balloons and drug-eluting stents hinders the peripheral vascular devices market growth by limiting access in cost-constrained healthcare systems. According to a peer-reviewed cost-effectiveness analysis of femoropopliteal interventions, drug-coated balloon angioplasty had initial costs that were $1,129 per patient higher than standard angioplasty because of the higher cost of the drug-coated balloon. This price disparity creates a barrier to adoption in public healthcare systems and developing regions where budget allocations for medical devices are strict. The statistical impact on procurement is evident as many hospital formularies restrict the use of premium devices to complex cases only, thereby limiting overall market volume. Additionally, reimbursement policies in several countries do not fully cover the incremental cost of drug-coated technologies, forcing providers to absorb the difference or pass it to patients. As per the European Society of Cardiology, guidelines recommend drug-coated devices for specific indications, but economic evaluations often delay their widespread implementation in national health services. These financial constraints restrict the penetration of next-generation products and force manufacturers to compete on price in the bare-metal segment. Consequently, the peripheral vascular devices market faces a persistent headwind where economic barriers limit the adoption of superior technologies that could improve long-term clinical outcomes.

Stringent Regulatory Approval Processes

Rigorous regulatory requirements and prolonged approval timelines for new peripheral vascular devices constrain the peripheral vascular devices market by delaying product launches and increasing development costs. According to the U.S. Food and Drug Administration, the statutory review period for a premarket approval application is 180 days from the filing date, although the actual review period can be affected by amendments and other regulatory interactions. This extended timeline slows the pace of innovation and prevents companies from quickly responding to emerging clinical needs, such as treatments for below-the-knee disease. The statistical burden of compliance is significant as manufacturers must provide substantial evidence of safety and effectiveness for Class III devices. Furthermore, varying regulatory standards across different regions, such as the European Union under the new Medical Device Regulation and Asia-Pacific, require manufacturers to conduct multiple submissions, which fragments resources. These bureaucratic hurdles discourage smaller innovators from entering the market and limit the diversity of available solutions. Thus, the peripheral vascular devices market is restricted by a complex regulatory environment that prioritizes patient safety but inadvertently stifles the speed of technological advancement and market expansion.

MARKET OPPORTUNITIES

Expansion into Below-the-Knee Interventions

The growing focus on treating infrapopliteal or below-the-knee arterial disease is a prominent opportunity for the peripheral vascular devices market by addressing a previously underserved clinical segment with high amputation risks. According to the American Heart Association, approximately 150,000 nontraumatic leg amputations occur every year in the United States, and peripheral artery disease and diabetes account for a substantial proportion of these events. Recent advancements in micro-catheters and low-profile balloons now enable safer navigation of these small-diameter vessels, opening new therapeutic avenues. The statistical potential is vast because the burden of lower extremity amputation highlights the need for effective below-the-knee revascularization. Manufacturers are developing specialized drug-coated balloons and bioresorbable scaffolds tailored for these delicate anatomies, which command premium pricing. According to a systematic review and meta-analysis published in the Journal of Vascular Surgery and related vascular literature, pooled 12-month limb salvage rates for below-the-knee drug-coated balloon treatment were approximately 94%. This niche expansion allows companies to differentiate their portfolios and capture high-value market share. Consequently, the peripheral vascular devices market can leverage this clinical unmet need to drive innovation and revenue growth in a segment with limited competition.

Integration of Robotics and Artificial Intelligence

The incorporation of robotic assistance and artificial intelligence into peripheral vascular procedures offers a substantial opportunity for the peripheral vascular devices market by enhancing precision and reducing radiation exposure. According to a prospective study published in the Journal of Invasive Cardiology, robotic peripheral vascular intervention reduced primary operator radiation exposure by 96.9% compared with table-side exposure during treatment of femoropopliteal lesions. This technological advantage appeals to interventionalists seeking to improve ergonomics and procedural accuracy in lengthy cases. The statistical improvement in technical success rates encourages hospitals to invest in robotic platforms, which require compatible disposable devices such as specialized catheters and guidewires. As per a recent systematic review and meta-analysis, robotic-assisted peripheral vascular intervention has been associated with markedly lower operator radiation exposure while demonstrating feasibility and safety across selected vascular procedures. Manufacturers who integrate smart sensors into their devices can capture valuable data that further refines these algorithms, creating a sticky ecosystem. This convergence of hardware and software creates new revenue streams beyond traditional device sales. Thus, the peripheral vascular devices market can capitalize on the digital transformation of the cath lab by offering integrated solutions that enhance clinical performance and operational efficiency.

MARKET CHALLENGES

Risk of Restenosis and Thrombosis

The inherent risk of vessel renarrowing (restenosis) and blood clot formation (thrombosis) poses a major challenge to the peripheral vascular devices market by necessitating repeat interventions and complicating patient management. According to the Journal of the American College of Cardiology, reported 1-year restenosis rates in pivotal bare-metal stent studies for femoropopliteal disease ranged from 31.7% to 47.2%. This clinical limitation erodes confidence in certain device classes and drives payers to demand evidence of long-term durability before covering new technologies. The statistical prevalence of adverse events leads to stringent post-market surveillance requirements and potential recalls, which damage brand reputation. As per the American College of Cardiology, thrombotic events remain a concern, particularly in patients with poor compliance to antiplatelet therapy, requiring devices with superior biocompatibility. These clinical realities force manufacturers to continuously refine materials and coatings to improve patency, but at the cost of slower adoption rates. Consequently, the peripheral vascular devices market faces ongoing scrutiny where clinical performance metrics directly influence purchasing decisions and market acceptance, requiring constant innovation to overcome biological limitations.

Shortage of Specialized Interventional Specialists

The limited number of physicians specifically trained in complex peripheral vascular interventions further challenges the peripheral vascular devices market by restricting the volume of procedures that can be performed effectively. According to a peer-reviewed workforce study published in the Journal of Vascular Surgery, 3,333 vascular surgeons were projected to be available in 2030 for approximately 180 million people with at least one risk factor for peripheral arterial disease, indicating a potential workforce shortage. This scarcity means that many community hospitals lack the internal capability to perform advanced endovascular procedures, leading to patient referrals to tertiary centers and delayed care. The statistical gap in specialized training limits the adoption of sophisticated devices that require precise technical skills for optimal placement, such as directional atherectomy systems. As per the Society for Cardiovascular Angiography and Interventions, the learning curve for new technologies is steep, requiring significant time and resource investment from hospitals for proctoring and simulation training. These human capital constraints hinder the widespread implementation of innovative devices. Thus, the peripheral vascular devices market must navigate a talent shortage that limits procedural capacity and slows the diffusion of advanced surgical technologies to broader geographic areas.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Product Type Insights

The stents segment led the market with 36.7% of the global peripheral vascular devices market share in 2025 due to their critical role in maintaining vessel patency following angioplasty and treating complex atherosclerotic lesions. The dominance of stents is driven by the high incidence of femoropopliteal artery disease, which affects the superficial femoral artery and popliteal artery, requiring robust mechanical support to prevent recoil. This anatomical prevalence creates a consistent and high-volume demand for both drug-eluting and bare-metal stents. The statistical correlation between lesion length and stent usage means that longer diseased segments require multiple overlapping stents, increasing the number of devices used per procedure. Furthermore, clinical guidelines increasingly recommend primary stenting for certain lesion types to improve primary patency rates compared to angioplasty alone. According to a randomized clinical trial published in JACC, the 1-year freedom from in-stent restenosis was 91% with a paclitaxel-eluting stent compared with 88.6% with a bare-metal stent in symptomatic femoropopliteal lesions. These clinical outcomes reinforce the preference for stenting in complex cases. Consequently, the peripheral vascular devices market relies on stents as its primary revenue generator, driven by the structural need to maintain blood flow in high-stress arterial segments subject to bending and compression.

On the other end, the chronic total occlusion devices segment is predicted to be the fastest growing segment with an expected CAGR of 9.3% over the forecast period owing to the complexity of treating completely blocked arteries, the shift toward limb salvage and the rising prevalence of critical limb ischemia, where complete arterial occlusion threatens limb viability and necessitates specialized recanalization tools. According to the American Heart Association, approximately 150,000 nontraumatic lower extremity amputations occur annually in the United States, highlighting the substantial unmet need for effective revascularization and limb salvage technologies. This severe clinical condition drives demand for dedicated chronic total occlusion devices, such as reentry catheters, crossing wires, and micro-dissection tools designed to navigate hard calcified plaques. The statistical urgency of preventing amputation ensures that hospitals invest in these specialized technologies despite their higher cost. Furthermore, the aging population and diabetes epidemic increase the incidence of long-segment occlusions, which are technically challenging to treat. According to a systematic review and meta-analysis of below-the-knee peripheral artery disease interventions, pooled 12-month freedom from target lesion revascularization was 86.0% with drug-coated balloons compared with 72.2% with standard angioplasty. This clinical necessity creates a dedicated market niche with limited alternatives. Consequently, the peripheral vascular devices market sees chronic total occlusion devices as a high-growth area driven by the imperative to save limbs and improve quality of life for the most severely affected patients.

REGIONAL ANALYSIS

North America Peripheral Vascular Devices Market Analysis

North America captured the largest share of the global peripheral vascular devices market in 2025 and is likely to maintain its leading position in the peripheral vascular devices market over the next few years because of its high disease burden, advanced healthcare infrastructure, and strong adoption of minimally invasive vascular technologies. North America holds the dominant position in the peripheral vascular devices market, characterized by high healthcare expenditure, advanced medical infrastructure, and a strong prevalence of peripheral artery disease. The region is home to major market players and leading research institutions that drive innovation. According to the Centers for Disease Control and Prevention, peripheral artery disease affects approximately 8.5 million Americans aged 40 and older, creating a large addressable patient population for vascular interventions. This high disease burden supports robust demand for both stents and adjunctive devices. Additionally, the presence of comprehensive insurance coverage, including Medicare, facilitates access to expensive procedures and devices. According to the National Heart, Lung, and Blood Institute, more than 300,000 surgical or endovascular lower extremity revascularization procedures are performed annually among Medicare beneficiaries with lower extremity peripheral artery disease without limb-threatening ischemia, reflecting substantial procedural capacity. Technological adoption is rapid, with early integration of drug-coated balloons and robotic assistance. According to Polaris Market Research, North America accounted for 38.54% of the global peripheral vascular device market in 2025, representing the largest regional share. These factors ensure North America remains the largest and most mature market globally.

Europe Peripheral Vascular Devices Market Analysis

Europe is likely to remain a significant and mature market for the peripheral vascular devices market over the next few years because of its aging population, established healthcare systems, and strong regulatory infrastructure. Europe occupies a significant and mature position in the peripheral vascular devices market, driven by an aging population and well-established healthcare systems that prioritize quality of life. The region has strict regulatory standards under the European Union Medical Device Regulation, which ensures high product safety and efficacy. According to Eurostat, the share of the population aged 65 and over reached approximately 21% in the European Union in 2023, driving demand for treatments for degenerative vascular conditions. This demographic trend supports steady growth in stent and balloon segments. Additionally, countries like Germany and the United Kingdom have strong interventional radiology communities that drive device utilization. As per the European Society of Cardiology, harmonization of clinical guidelines across member states facilitates consistent adoption of best practices. Reimbursement policies vary by country but generally support necessary interventions. These dynamics position Europe as a key market for high-quality and regulated peripheral vascular devices.

Asia-Pacific Peripheral Vascular Devices Market Analysis

The Asia-Pacific region is likely to deliver the fastest growth in the peripheral vascular devices market over the next few years because of its large aging population, rising diabetes burden, expanding healthcare infrastructure, and increasing adoption of minimally invasive interventions. The Asia-Pacific region represents the fastest-growing segment in the peripheral vascular devices market, driven by improving healthcare infrastructure, rising disposable incomes, and increasing awareness of advanced treatment options. Countries like China, Japan, and India are seeing rapid expansion in vascular services. According to the International Diabetes Federation, China had approximately 140.9 million adults living with diabetes in 2021, representing the largest national diabetes population in the world and creating a substantial pool of patients at risk of vascular complications. The rising middle class is increasingly willing to pay for premium devices and surgeries. Additionally, the prevalence of diabetes and smoking is increasing in the region, contributing to higher rates of peripheral artery disease. As per the International Diabetes Federation, China has the largest number of diabetic patients globally, creating a vast market for vascular interventions. Local manufacturing capabilities are also improving, reducing costs and increasing availability. According to Polaris Market Research, Asia-Pacific is expected to register the fastest regional growth at a CAGR of 7.25% during the forecast period. These factors indicate that Asia-Pacific will be the primary driver of future global market growth.

Latin America Peripheral Vascular Devices Market Analysis

Latin America is likely to experience steady expansion in the peripheral vascular devices market over the next few years as urbanization, healthcare access, and the burden of chronic diseases support demand for vascular interventions. Latin America holds an emerging position in the peripheral vascular devices market, characterized by growing medical tourism and gradual improvements in healthcare access. Brazil and Mexico are the largest markets in the region, driven by urbanization and increasing cardiovascular disease prevalence. According to the World Bank, approximately 80% of the population of Latin America and the Caribbean lives in urban areas and this support the expansion of modern healthcare facilities and access to specialized medical services. Medical tourism attracts patients from North America seeking affordable yet high-quality surgical care, boosting device utilization in private hospitals. As per the Brazilian Society of Angiology and Vascular Surgery, endovascular treatment has become an established component of peripheral arterial disease management in Brazil. However, economic volatility and uneven insurance coverage remain challenges. Despite these hurdles, the region shows potential for growth as infrastructure develops and awareness increases. These dynamics suggest Latin America is a developing market with untapped potential.

Middle East and Africa Peripheral Vascular Devices Market Analysis

The Middle East and Africa region is likely to witness gradual growth in the peripheral vascular devices market over the next few years because of its high diabetes burden, young population, and increasing investment in healthcare infrastructure, particularly in Gulf countries. The Middle East and Africa region represents a nascent but evolving segment in the peripheral vascular devices market, driven by the high prevalence of diabetes and increasing investment in healthcare infrastructure in Gulf countries. The United Arab Emirates and Saudi Arabia are leading adoption due to government initiatives to improve healthcare quality. According to the International Diabetes Federation, the Middle East and North Africa region had one of the highest age-adjusted comparative prevalences of diabetes globally at approximately 16.2% in 2021, driving significant demand for vascular interventions to prevent complications. This specific clinical need shapes the market profile towards advanced stenting and limb salvage technologies. Additionally, rising obesity rates contribute to higher incidence of peripheral artery disease. As per the World Health Organization, healthcare expenditure in Gulf Cooperation Council countries continues to support investment in advanced medical infrastructure and specialist services. However, a lack of specialized surgeons and limited reimbursement in African nations restrict broader market penetration. These factors position the region as a niche market with specific high-value opportunities.

COMPETITIVE LANDSCAPE

The competition in the Peripheral Vascular Devices Market is characterized by intense rivalry among established multinational corporations and specialized niche players who compete on technological superiority and clinical evidence. Large entities leverage their broad product portfolios and global distribution networks to dominate hospital accounts while smaller firms focus on innovative solutions for specific indications such as below the knee disease or venous disorders. The barrier to entry is high due to stringent regulatory requirements and the need for extensive clinical data to prove safety and efficacy. Competitive intensity is driven by the rapid pace of technological advancement including drug coating innovations and robotic assistance which forces continuous investment in research and development. Price competition exists but is secondary to product performance and long term patency rates which are critical for adoption. Reimbursement policies and health technology assessments further shape competitive dynamics by influencing market access and profitability. This environment requires participants to demonstrate clear clinical benefits and provide robust support services to maintain market share and drive growth in a sophisticated medical device sector.

KEY MARKET PARTICIPANTS

Companies playing a promising role in the global peripheral vascular devices market profiled in the report are

• Abbott Laboratories
• Angioscore
• Boston Scientific Corporation
• Bayer AG
• Emboline Inc.

Top Players in the Market

Medtronic plc

Medtronic plc maintains a robust presence in the Peripheral Vascular Devices Market through its comprehensive portfolio of drug coated balloons stents and atherectomy systems. The company leverages advanced manufacturing technologies to produce high quality implants that support complex endovascular procedures. Recently Medtronic expanded its clinical evidence base by launching large scale trials for next generation drug eluting technologies aimed at reducing restenosis rates. This commitment to innovation strengthens relationships with interventionalists who prioritize long term patient outcomes. By offering integrated solutions from diagnosis to treatment Medtronic ensures seamless procedural workflows. Their strategic focus on limb salvage programs enhances brand loyalty among vascular surgeons. These actions solidify their reputation as a leader in providing reliable and advanced peripheral vascular care products globally.

Boston Scientific Corporation

Boston Scientific Corporation plays a pivotal role in the Peripheral Vascular Devices Market by combining extensive global reach with specialized expertise in minimally invasive therapies. The company offers a diverse range of devices including Ranger paclitaxel coated balloons and Viatrac peripheral stent systems designed for durability. Recently Boston Scientific introduced new lithotripsy technologies to treat heavily calcified lesions which are common in diabetic patients. This material innovation addresses complex clinical challenges and improves procedural success rates. They also invest heavily in physician education programs to promote best practices in chronic total occlusion interventions. Through strategic partnerships with hospitals Boston Scientific improves access to advanced care. These efforts reinforce their competitive edge and drive adoption of their premium product lines in key international markets.

Abbott Laboratories

Abbott Laboratories contributes significantly to the Peripheral Vascular Devices Market through its focus on innovative stent platforms and vascular closure solutions. The company specializes in drug eluting stents such as the Xience family which are widely used for peripheral artery disease. Recently Abbott launched enhanced delivery systems for its stents that improve navigability in tortuous anatomy. This product expansion targets the growing demand for precise and safe device placement in complex cases. They also collaborate with research institutions to validate clinical performance in real world settings. By prioritizing surgeon feedback and clinical evidence Abbott builds strong brand trust. These actions enhance their market position by addressing specific needs of the vascular community and expanding their footprint in ambulatory surgical centers.

Top Strategies Used by Key Market Participants

Key players in the Peripheral Vascular Devices Market primarily employ product innovation strategies by developing advanced drug coated technologies and specialized tools for chronic total occlusions to improve clinical outcomes. Companies invest heavily in research and development to create bioresorbable scaffolds and intravascular lithotripsy systems that address complex calcified lesions. Another major strategy involves expanding into emerging markets where healthcare infrastructure is improving and demand for peripheral interventions is rising due to aging populations. Manufacturers establish local distribution partnerships to navigate regulatory requirements and reduce costs effectively. Additionally participants focus on physician training and proctoring programs to build loyalty and ensure proper utilization of complex devices. Strategic acquisitions of smaller innovative firms allow large corporations to integrate new technologies quickly. These combined tactics enable companies to maintain leadership and capture growth in a competitive and evolving industry landscape.

RECENT MARKET DEVELOPMENTS

• In November 2020, Boston Scientific Corporation received the U.S FDA acceptance for the Ranger Drug-Coated Balloon. The balloon is developed for treating patients with peripheral artery disease (PAD). 
• In September 2020, Abbott launched the LIFE-BTK clinical trial to estimate the safety and effectiveness of the company's new Resorbable Scaffold System. This is used to treat blocked arteries in people fighting against peripheral artery disease (PAD). 
• In Jan 2020, Emboline Inc. stated that they completed the enrollment for the Safepass 2 clinical study of the Emboliner Embolic Protection Catheter.
• On July 15, 2019, Bayer released a statement that the FDA approved Gadavist injection for the cardiac magnetic resonance imaging (MRI) technique. 
• In July 2017, The Spectranetics Corporation received U.S FDA approval for Stellarex drug-coated balloon, designed to restore and maintain the blood flow to the superficial femoral and popliteal arteries in patients with PAD.

MARKET SEGMENTATION

This research report on the global peripheral vascular devices market has been segmented and sub-segmented into the following categories.

By Product Type

• Stents
  • Balloon-Expandable Stent
  • Self-Expandable Stents
  • Secured Stents
• Embolic Protection Devices
• Angioplasty Balloons
  • Ordinary
  • Cutting
  • Scoring
  • Medication
• Aortic Stent-Grafts
• Inferior Vena Cava Filters
• Synthetic Surgical Grafts
• Peripheral Vascular Accessory Devices
• Vascular Closure Devices
• Chronic Total Occlusion (CTO) Devices
• PTA Balloon Catheters

By Material

• Resistant
• Semi-Consistent Sorts

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa